This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information
Key reasons to purchase this title
- Benchmark Bayer Schering Pharmas performance against key rivals in the ethical pharmaceutical sector
- Analyse how Bayers acquisition of Schering AG in 2006 has notably enhanced the companys HealthCare division
- Assess how an increased healthcare focus and merger-related synergies will drive an increase in operating profit at an 8.4% CAGR over 200814
